Arthrogryposis multiplex congenita (AMC) is characterized by the presence of multiple joint contractures resulting from reduced or absent fetal movement. Here, we report two unrelated families affected by lethal AMC. By genetic mapping and whole-exome sequencing in a multiplex family, a heterozygous truncating MAGEL2 mutation leading to frameshift and a premature stop codon (c.1996delC, p.Gln666Serfs*36) and inherited from the father was identified in the probands. In another family, a distinct heterozygous truncating mutation leading to frameshift (c.2118delT, p.Leu708Trpfs*7) and occurring de novo on the paternal allele of MAGEL2 was identified in the affected individual. In both families, RNA analysis identified the mutated paternal MAGEL2 transcripts only in affected individuals. MAGEL2 is one of the paternally expressed genes within the Prader-Willi syndrome (PWS) locus. PWS is associated with, to varying extents, reduced fetal mobility, severe infantile hypotonia, childhood-onset obesity, hypogonadism, and intellectual disability. MAGEL2 mutations have been recently reported in affected individuals with features resembling PWS and called Schaaf-Yang syndrome. Here, we show that paternal MAGEL2 mutations are also responsible for lethal AMC, recapitulating the clinical spectrum of PWS and suggesting that MAGEL2 is a PWS-determining gene.
Arthrogryposis multiplex congenita (AMC) is characterized by the presence of multiple joint contractures resulting from reduced or absent fetal movement. Here, we report two unrelated families affected by lethal AMC. By genetic mapping and whole-exome sequencing in a multiplex family, a heterozygous truncating MAGEL2 mutation leading to frameshift and a premature stop codon (c.1996delC, p.Gln666Serfs*36) and inherited from the father was identified in the probands. In another family, a distinct heterozygous truncating mutation leading to frameshift (c.2118delT, p.Leu708Trpfs*7) and occurring de novo on the paternal allele of MAGEL2 was identified in the affected individual. In both families, RNA analysis identified the mutated paternal MAGEL2 transcripts only in affected individuals. MAGEL2 is one of the paternally expressed genes within the Prader-Willi syndrome (PWS) locus. PWS is associated with, to varying extents, reduced fetal mobility, severe infantile hypotonia, childhood-onset obesity, hypogonadism, and intellectual disability. MAGEL2 mutations have been recently reported in affected individuals with features resembling PWS and called Schaaf-Yang syndrome. Here, we show that paternal MAGEL2 mutations are also responsible for lethal AMC, recapitulating the clinical spectrum of PWS and suggesting that MAGEL2 is a PWS-determining gene.
Arthrogryposis multiplex congenita (AMC) has an overall incidence of one in 3,000 live births. The parents of all affected individuals provided written informed consent for genetic analysis of their children or fetuses and themselves in accordance with the ethical standards of our institutional review boards. In family 1, three affected fetuses were born to non-consanguineous healthy parents (Figure 1 ). According to ultrasound examination, the first fetus displayed reduced mobility detectable from 22 weeks of gestation (w.g.) and associated with polyhydramnios and unilateral club foot. Karyotype analysis was 46, XX. Fetal death was observed at 24 w.g. Fetopathological examination revealed severe microretrognathia associated with short palpebral fissures, hypertelorism, a short and large neck, bilateral club foot, flexion of elbows and knees, and camptodactyly of the fingers ( Figure S1 ). For the second fetus, ultrasound examination revealed bilateral club foot associated with polyhydramnios and bilateral camptodactyly at 23 w.g. Fetal death was observed at 24 w.g. Pathological examination revealed an identical phenotype in this male fetus. Morphological examination of the brain, spinal cord, and the neuromuscular system did not reveal any specific defect. The third fetus, a male, was also affected with an identical phenotype and died at 27 w.g. Figure 1 ), was identified within the 15q11.2 region, one of the linked disease loci ( Figure 1 ). Sanger sequencing of PCR products via primers flanking the mutation (Table S1 ) confirmed the mutation in the three affected fetuses (III:1 to III:3; Figure 1 ) and showed that it was inherited from the unaffected father (II:2; Figure 1 ). Analysis of the father's parents indicated that the mutation was inherited from the unaffected grandmother (I:2; Figure 1 ). Via both WES and microarray data, a total of 240 SNPs were identified in this family at the Prader-Willi locus at an average distance of 6.4 Kb. In 140 of them, heterozygosity was observed in the affected fetuses. At the SNORD116 snoRNA cluster, 79 out of 87 SNPs were found to be heterozygous (data not shown, available on request). These data exclude a large heterozygous deletion or maternal uniparental disomy at this locus. Given that MAGEL2 is only expressed from the paternal allele, MAGEL2 RNA analysis was performed from skeletal muscle of an affected fetus. Because MAGEL2 is a single-exon gene, and to avoid contamination of RNA by DNA, RNA was treated with DNase RNase-Free (Macherey-Nagel). Then, MAGEL2 PCR analysis was performed from RNA before or after reverse transcription (SuperScript III Reverse Transcriptase, Invitrogen, Table S1 ). In comparison to b-actin expression in control RNA, a marked reduction of MAGEL2 expression was observed in affected individuals ( Figure 1) . Importantly, sequence analysis of RT-PCR product revealed the paternally mutated allele, only indicating the absence of maternally expressed MAGEL2 allele in the affected individuals ( Figure 1 and Table S1 ). Sanger sequencing of MAGEL2 in additional affected individuals or fetuses with arthrogryposis and/or reduced fetal mobility (n ¼ 84) of unknown origin allowed the identification of a distinct truncating mutation of MAGEL2 in another affected individual (II:1, family 2; Figure 2 ). In this family, the female affected individual was born to non-consanguineous healthy parents. The abnormal phenotype was discovered at birth and was characterized by microretrognathia, a short neck, bilateral camptodactyly of the third and fourth fingers, and bilateral club foot. The newborn displayed severe hypotonia with respiratory distress from birth and died at postnatal day 2. Pathological examination of the brain, spinal cord, and other organs was normal. Array comparative genomic hybridization was normal, as well as Sanger sequencing of CHRNG, CHRNA1, CHRNB1, CHRND, RAPSN, DOK7, and CHAT. The DMPK locus was normal. Paternal deletion of 15q11-15q13 and maternal uniparental disomy 15 were excluded. Through sequencing of MAGEL2, a heterozygous 1 bp deletion in MAGEL2 (c.2118delT [GenBank: NM_019066.4]), leading to frameshift and a stop codon (p.Leu708Trpfs*7; Figure 2 and Table S1 ), was identified in this affected individual (II:1). Analysis of both parents showed that the mutation had occurred de novo. To determine whether the de novo MAGEL2 mutation occurred on the paternal or maternal allele, MAGEL2 RNA analysis was performed from affected-individual fibroblasts. Sequence analysis of RT-PCR was performed via primers flanking the frameshift deletion as well as a SNP (rs2233070) located in MAGEL2 and inherited from the mother (I:2; Figure 2 and Table S1 ). Importantly, sequence analysis of RT-PCR product revealed the frameshift deletion allele only and the lack of the maternal SNP allele, indicating that the deleterious de novo MAGEL2 mutation occurred on the paternal allele (II:1; Figure 2 ). Marked reduction of MAGEL2 expression was observed in the affected individual (data not shown). These two truncating mutations were found neither in the current Exome Variant Server database (ESP6500SI-V2) nor in the Single Nucleotide Polymorphism Database (dbSNP v.144). MAGEL2 is one of the paternally expressed genes located within the Prader-Willi syndrome (PWS) locus. PWS is associated with, to varying extents, reduced fetal mobility, distal joint contractures, neonatal hypotonia with respiratory distress, early-childhood-onset obesity, intellectual disability, hypogonadotropic hypogonadism, and short stature. PWS can result from paternal deletion of 15q11-15q13 (in 65%-75% of affected individuals), maternal uniparental disomy 15 (in 20%-30% of affected individuals), or, more rarely, an imprinting defect or microdeletion including the SNORD116 cluster (reviewed in Cassidy et al. 9 ). The Prader-Willi locus contains five paternally expressed genes (MKRN3, MAGEL2, NDN, NPAP1, and SNURF-SNRPN) and a family of six paternally expressed snoRNA genes or clusters. 9 PWS has been suggested as being a contiguous gene syndrome. PWS has been reported in fetuses with polyhydramnios associated with reduced fetal mobility and distal arthrogryposis. [10] [11] [12] [13] In these cases, paternal 15q11-15q13 deletion or maternal uniparental disomy of 15q11.2-15q12 were identified, and it was suggested that PWS should be considered in fetuses with polyhydramnios and/or abnormal fetal position, especially if diminished fetal movements are reported. Here, we report four affected individuals from two unrelated families who have a phenotype very similar to those previously reported [10] [11] [12] [13] and who carry heterozygous truncating mutations on the paternal allele of MAGEL2. These mutations are either inherited from or occurred de novo on the paternal allele, indicating that truncating mutations in MAGEL2 are responsible for this condition. Appropriate genetic information from other members of the family might need to be provided, especially when a paternally mutated allele identified in affected individuals is transmitted silently from the grandmother.
Recently, truncating mutations of MAGEL2 have been identified on the paternal allele of four affected individuals with features resembling PWS and called Schaaf-Yang syndrome (MIM: 615547). 14, 15 However, another affected individual carrying a large paternally inherited deletion of 3.9 Mb that includes MAGEL2, but not the SNRPN-SNORD116 locus, was reported as not showing intellectual disability at 3 years of age, but did show transient neonatal hypotonia associated with a slight delay of fine motor skills. 16 These data revealed that intragenic mutations or deletion of the paternal allele of MAGEL2 result in a large clinical spectrum, ranging from a severe fetal phenotype characterized by polyhydramnios, reduced fetal mobility and distal joint contractures (our report), and syndromic intellectual disability or autism (Schaaf-Yang syndrome) 14, 15 to an abnormal position of distal joints with a slight delay of fine motor skills without intellectual disability. 16 Of note, three out of four affected individuals reported by Schaaf et al. 14 displayed neonatal hypotonia and feeding problems with the need for special feeding techniques, and in two out of four affected individuals, contractures of the proximal and distal interphalangeal joints were reported. These data strongly support the view that MAGEL2 intragenic mutations recapitulate the PWS phenotype. Recently, Matarazzo and Muscatelli (2013) 17 detected
Magel2 transcripts in the brains of mice deleted for the paternal allele of Magel2, indicating an incomplete silencing of the maternal allele. Interestingly, paternally Magel2-null mice have reduced embryonic viability (in 10% to 30% of embryos) but otherwise normal embryonic growth in survivors, followed by post-natal growth retardation and excessive weight gain, recapitulating aspects of the PWS phenotype. 18, 19 Similarly, Guo et al. 20 have reported an imprinting variance of Magel2 in pigs during fetal development. These data suggest that the imprinting pattern of MAGEL2, as well as other genes at the PWS locus, could be regulated during development by trans effects on the maternal allele. We hypothesize that the clinical expression of PWS might depend on the temporal or spatial variation in expression of the maternal MAGEL2 allele and that a complete lack of maternal MAGEL2 allele expression is responsible for early-onset and very severe disease phenotypes. However, we cannot exclude a role of other genes linked or not to the PWS locus in the clinical expression of PWS. During mouse embryogenesis, Magel2 expression is restricted to the neural tube, forebrain, midbrain, and hypothalamus, as well as to the dorsal root ganglia and peripheral neurons innervating limb and trunk muscles. 19 In non-neuronal tissues, Magel2 expression is confined to the genital tubercle, midgut region, and placenta. In affected individuals with PWS, neuromuscular studies including muscle biopsy are generally normal or show non-specific signs suggesting that the motor deficit is of central origin. The expression pattern of MAGEL2 in the CNS during development and the fetal onset of motor defects associated with truncating mutations of MAGEL2 reported here strongly suggest that MAGEL2 has an essential role in neuronal development. The expression pattern of maternal MAGEL2 warrants further investigation in the nervous system during development. Altogether, these data strongly suggest that MAGEL2 is a PWS-determining gene. In the absence of paternal deletion of 15q11-15q13 or maternal uniparental disomy 15, a search for intragenic mutations on the paternal allele of MAGEL2 should be proposed for fetuses with reduced movements, polyhydramnios, and distal arthrogryposis, newborns with severe undiagnosed central hypotonia, or children for whom PWS is clinically suspected.
Supplemental Data
Supplemental Data include one figure and one table and can be found with this article online at http://dx.doi.org/10.1016/j. ajhg.2015.08.010. 
